Please login to the form below
BMS and Pfizer's Eliquis in trial success
Bristol-Myers Squibb and Pfizer have revealed successful topline results of the phase III ARISTOTLE trial of Eliquis (apixaban) for atrial fibrillation
Bristol-Myers Squibb (BMS) and Pfizer have revealed successful topline results of the phase III ARISTOTLE trial of Eliquis (apixaban) for atrial fibrillation.
In this study of patients with atrial fibrillation and at least one additional risk factor for stroke, Eliquis met the primary efficacy objective of non-inferiority to warfarin on the combined outcome of stroke (ischemic, hemorrhagic or unspecified type) and systemic embolism.
The drug met the key secondary endpoints of superiority on efficacy and on International Society on Thrombosis and Hemostasis major bleeding compared to warfarin.
Eliquis, a new oral direct Factor Xa inhibitor, is being developed by the alliance of BMS and Pfizer.
The companies expect to submit regulatory filings in atrial fibrillation in the US and Europe in the third or fourth quarter of 2011.
The detailed results of the ARISTOTLE study will be presented on August 28 at the European Society of Cardiology Congress 2011 in Paris.
Share
Related Hub content
Subscribe to our email news alerts
- No “White Space” Between Live Meetings; the top 10 benefits of virtual advisory boards
- Building trust with HCPs: 6 takeaways from our industry webinar
- Eli Lilly and PRISM BioLab enter drug discovery collaboration worth over $660m
- NHS to offer stem cell transplants to patients living with rare blood disorder
- First WHO Global Clinical Trial Forum develops joint vision to improve clinical research
- Merck shares positive phase 3 results for investigational pneumococcal vaccine in adults
No results were found
PMHub
An agency called Owen
We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
